Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

Ichiro Hanamura, James P. Stewart, Yongsheng Huang, Fenghuang Zhan, Madhumita Santra, Jeffrey R. Sawyer, Klaus Hollmig, Maurizio Zangarri, Mauricio Pineda-Roman, Frits Van Rhee, Federica Cavallo, Bart Burington, John Crowley, Guido Tricot, Bart Barlogie, John D. Shaughnessy

Research output: Contribution to journalArticle

297 Citations (Scopus)

Abstract

Using fluorescence in situ hybridization we investigated amplification of chromosome band 1q21 (Amp1q21) in more than 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS; n = 14), smoldering multiple myeloma (SMM; n = 31), and newly diagnosed MM (n = 479) as well as 45 with relapsed MM. The frequency of Amp1q21 was 0% in MGUS, 45% in SMM, 43% in newly diagnosed MM, and 72% in relapsed MM (newly diagnosed versus relapsed MM, P < .001). Amp1q21 was detected in 10 of 12 patients whose disease evolved to active MM compared with 4 of 19 who remained with SMM (P < .001). Patients with newly diagnosed MM with Amp1q21 had inferior 5-year event-free/overall survival compared with those lacking Amp1q21 (38%/52% versus 62%/78%, both P < .001). Thalidomide improved 5-year EFS in patients lacking Amp1q21 but not in those with Amp1q21 (P = .004). Multivariate analysis including other major predictors revealed that Amp1q21 was an independent poor prognostic factor. Relapsed patients who had Amp1q21 at relapse had inferior 5-year postrelapse survival compared with those lacking Amp1q21 at relapse (15% versus 53%, P = .027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis.

Original languageEnglish (US)
Pages (from-to)1724-1732
Number of pages9
JournalBlood
Volume108
Issue number5
DOIs
StatePublished - Sep 1 2006

Fingerprint

Paraproteinemias
Stem Cell Transplantation
Chromosomes
Stem cells
Fluorescence In Situ Hybridization
Disease Progression
Fluorescence
Plasmas
Thalidomide
Incidence
Amplification
Recurrence
Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Disease-Free Survival
Multivariate Analysis
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization : Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. / Hanamura, Ichiro; Stewart, James P.; Huang, Yongsheng; Zhan, Fenghuang; Santra, Madhumita; Sawyer, Jeffrey R.; Hollmig, Klaus; Zangarri, Maurizio; Pineda-Roman, Mauricio; Van Rhee, Frits; Cavallo, Federica; Burington, Bart; Crowley, John; Tricot, Guido; Barlogie, Bart; Shaughnessy, John D.

In: Blood, Vol. 108, No. 5, 01.09.2006, p. 1724-1732.

Research output: Contribution to journalArticle

Hanamura, I, Stewart, JP, Huang, Y, Zhan, F, Santra, M, Sawyer, JR, Hollmig, K, Zangarri, M, Pineda-Roman, M, Van Rhee, F, Cavallo, F, Burington, B, Crowley, J, Tricot, G, Barlogie, B & Shaughnessy, JD 2006, 'Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation', Blood, vol. 108, no. 5, pp. 1724-1732. https://doi.org/10.1182/blood-2006-03-009910
Hanamura, Ichiro ; Stewart, James P. ; Huang, Yongsheng ; Zhan, Fenghuang ; Santra, Madhumita ; Sawyer, Jeffrey R. ; Hollmig, Klaus ; Zangarri, Maurizio ; Pineda-Roman, Mauricio ; Van Rhee, Frits ; Cavallo, Federica ; Burington, Bart ; Crowley, John ; Tricot, Guido ; Barlogie, Bart ; Shaughnessy, John D. / Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization : Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. In: Blood. 2006 ; Vol. 108, No. 5. pp. 1724-1732.
@article{7a9237f857b24e66b0f313ee6b584e44,
title = "Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation",
abstract = "Using fluorescence in situ hybridization we investigated amplification of chromosome band 1q21 (Amp1q21) in more than 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS; n = 14), smoldering multiple myeloma (SMM; n = 31), and newly diagnosed MM (n = 479) as well as 45 with relapsed MM. The frequency of Amp1q21 was 0{\%} in MGUS, 45{\%} in SMM, 43{\%} in newly diagnosed MM, and 72{\%} in relapsed MM (newly diagnosed versus relapsed MM, P < .001). Amp1q21 was detected in 10 of 12 patients whose disease evolved to active MM compared with 4 of 19 who remained with SMM (P < .001). Patients with newly diagnosed MM with Amp1q21 had inferior 5-year event-free/overall survival compared with those lacking Amp1q21 (38{\%}/52{\%} versus 62{\%}/78{\%}, both P < .001). Thalidomide improved 5-year EFS in patients lacking Amp1q21 but not in those with Amp1q21 (P = .004). Multivariate analysis including other major predictors revealed that Amp1q21 was an independent poor prognostic factor. Relapsed patients who had Amp1q21 at relapse had inferior 5-year postrelapse survival compared with those lacking Amp1q21 at relapse (15{\%} versus 53{\%}, P = .027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis.",
author = "Ichiro Hanamura and Stewart, {James P.} and Yongsheng Huang and Fenghuang Zhan and Madhumita Santra and Sawyer, {Jeffrey R.} and Klaus Hollmig and Maurizio Zangarri and Mauricio Pineda-Roman and {Van Rhee}, Frits and Federica Cavallo and Bart Burington and John Crowley and Guido Tricot and Bart Barlogie and Shaughnessy, {John D.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1182/blood-2006-03-009910",
language = "English (US)",
volume = "108",
pages = "1724--1732",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization

T2 - Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

AU - Hanamura, Ichiro

AU - Stewart, James P.

AU - Huang, Yongsheng

AU - Zhan, Fenghuang

AU - Santra, Madhumita

AU - Sawyer, Jeffrey R.

AU - Hollmig, Klaus

AU - Zangarri, Maurizio

AU - Pineda-Roman, Mauricio

AU - Van Rhee, Frits

AU - Cavallo, Federica

AU - Burington, Bart

AU - Crowley, John

AU - Tricot, Guido

AU - Barlogie, Bart

AU - Shaughnessy, John D.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Using fluorescence in situ hybridization we investigated amplification of chromosome band 1q21 (Amp1q21) in more than 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS; n = 14), smoldering multiple myeloma (SMM; n = 31), and newly diagnosed MM (n = 479) as well as 45 with relapsed MM. The frequency of Amp1q21 was 0% in MGUS, 45% in SMM, 43% in newly diagnosed MM, and 72% in relapsed MM (newly diagnosed versus relapsed MM, P < .001). Amp1q21 was detected in 10 of 12 patients whose disease evolved to active MM compared with 4 of 19 who remained with SMM (P < .001). Patients with newly diagnosed MM with Amp1q21 had inferior 5-year event-free/overall survival compared with those lacking Amp1q21 (38%/52% versus 62%/78%, both P < .001). Thalidomide improved 5-year EFS in patients lacking Amp1q21 but not in those with Amp1q21 (P = .004). Multivariate analysis including other major predictors revealed that Amp1q21 was an independent poor prognostic factor. Relapsed patients who had Amp1q21 at relapse had inferior 5-year postrelapse survival compared with those lacking Amp1q21 at relapse (15% versus 53%, P = .027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis.

AB - Using fluorescence in situ hybridization we investigated amplification of chromosome band 1q21 (Amp1q21) in more than 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS; n = 14), smoldering multiple myeloma (SMM; n = 31), and newly diagnosed MM (n = 479) as well as 45 with relapsed MM. The frequency of Amp1q21 was 0% in MGUS, 45% in SMM, 43% in newly diagnosed MM, and 72% in relapsed MM (newly diagnosed versus relapsed MM, P < .001). Amp1q21 was detected in 10 of 12 patients whose disease evolved to active MM compared with 4 of 19 who remained with SMM (P < .001). Patients with newly diagnosed MM with Amp1q21 had inferior 5-year event-free/overall survival compared with those lacking Amp1q21 (38%/52% versus 62%/78%, both P < .001). Thalidomide improved 5-year EFS in patients lacking Amp1q21 but not in those with Amp1q21 (P = .004). Multivariate analysis including other major predictors revealed that Amp1q21 was an independent poor prognostic factor. Relapsed patients who had Amp1q21 at relapse had inferior 5-year postrelapse survival compared with those lacking Amp1q21 at relapse (15% versus 53%, P = .027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=33748196399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748196399&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-03-009910

DO - 10.1182/blood-2006-03-009910

M3 - Article

C2 - 16705089

AN - SCOPUS:33748196399

VL - 108

SP - 1724

EP - 1732

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -